Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Robustness of CRC749 (Wixela Inhub) in Asthma/COPD
NCT02474017Phase 1Completed
- Sponsor
- Mylan
- Start
- May 2015
- Primary completion
- Jun 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of salmeterol + fluticasone in asthma and chronic obstructive pulmonary disease (COPD), sponsored by Mylan. Primary endpoint: In vitro Measurement of Emitted Dose at 3 weeks. Started May 2015; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02474017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474017.